Market Overview

UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Share:

Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.

Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients."

Rexahn Pharmaceuticals closed at $0.29 on Thursday.

Latest Ratings for RNN

DateFirmActionFromTo
Jul 2018Initiates Coverage OnBuy
Oct 2017Initiates Coverage OnBuy
Apr 2017Initiates Coverage OnBuy

View More Analyst Ratings for RNN
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (RNN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on Cepheid